Artemide Hcc01 First Line Rilvegostomig Plus Bevacizumab In Uhcc

Summary

Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, comments on the rationale and design of ... Amit Mahipal, MD, of University Hospitals discusses a recent study on atezolizumab Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, discusses the results of a multinational, multicenter, ... Federica Lo Prinzi, MD, Fondazione Policlinico Universitario Campus Bio- Medico, Rome, Italy, comments on a retrospective ... Patients with newly diagnosed advanced biliary tract cancer are often treated with immunotherapy So the trial was initiated and I think we didn't expect to see such promising results and for the Michael J. Pishvaian, MD, PhD, a gastrointestinal oncologist and head of the Phase I Program at the Georgetown Lombardi ... Lipika Goyal, MD, a hematologist and medical oncologist at Massachusetts General Hospital, discusses Julien Edeline, MD, PhD, Centre Eugene Marquis, Rennes, France, discusses four-year -up data from the CHIEF French ... Peter R. Galle, MD, the director of the Medical Department at the University Medical Center Mainz and president-elect of the ... Michael Pishvaian, MD, PhD, of Georgetown University, Washington, WA, describes the process and outcomes of the Phase 1b ... Pierce Chow, MBBS, MMed (Surg), FRCS (Edin), FAMS (Gen Surg), PhD, National Cancer Centre Singapore & Duke-NUS ... Stephen Chan, MBBS, MRCP, The Chinese University of Hong Kong, Hong Kong, China, discusses the Phase III EMERALD-1 ... ... F targeted antibody and this was done in the front Dr. Hochster, Distinguished Professor of Medicine, Rutgers Cancer Institute, on whether Tecentriq (atezolizumab) +